, Recherche de facteurs associés à la réponse objective dans le sous groupe de patients atteints de carcinomes bronchiques Bibliographie : 1. Population par sexe et groupe d'âges en 2019 | Insee, Tableau, vol.18

D. Sur, Projection de l'incidence et de la mortalité par cancer en France métropolitaine en, 2017.

, / Maladies chroniques et traumatismes / Rapports et synthèses / Publications et outils / Accueil [Internet

D. Sur,

, Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018 / 2019 / Maladies chroniques et traumatismes / Rapports et synthèses / Publications et outils / Accueil

D. Sur,

L. Balducci, Geriatric oncology: challenges for the new century, Eur J Cancer Oxf Engl, vol.36, issue.14, pp.1741-54, 1990.

O. Alkharabsheh, P. Kannarkatt, J. Kannarkatt, L. Karapetyan, H. S. Laird-fick et al., An overview of the toxicities of checkpoint inhibitors in older patients with cancer, J Geriatr Oncol. sept, vol.9, issue.5, pp.451-459, 2018.

A. Daste, C. Domblides, M. Gross-goupil, C. Chakiba, A. Quivy et al., Immune checkpoint inhibitors and elderly people: A review, Eur J Cancer. sept, vol.82, pp.155-66, 2017.

R. Elias, J. Morales, Y. Rehman, and H. Khurshid, Immune Checkpoint Inhibitors in Older Adults, Curr Oncol Rep, 2016.

. Herin, 2018 -Immunotherapy phase I trials in patients Older tha

C. Sofog-;-fortpied, U. Wedding, M. C. Van-nes, B. Penninckx, and A. Ring, EORTC elderly task force position paper: approach to the older cancer patient, Eur J Cancer Oxf Engl, vol.46, issue.9, pp.1502-1515, 1990.

M. M. Oken, R. H. Creech, D. C. Tormey, J. Horton, T. E. Davis et al., Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol. déc, vol.5, issue.6, pp.649-55, 1982.

Y. Guigoz, B. Vellas, and P. J. Garry, Assessing the Nutritional Status of the Elderly: The Mini Nutritional Assessment as Part of the Geriatric Evaluation, Nutr Rev. 27 avr, vol.54, issue.1, 2009.

S. Katz, T. D. Downs, H. R. Cash, and R. C. Grotz, Progress in Development of the Index of ADL, The Gerontologist. 1 mars, vol.10, issue.1_Part_1, pp.20-30, 1970.

M. P. Lawton and E. M. Brody, Assessment of older people: self-maintaining and instrumental activities of daily living, The Gerontologist, vol.9, issue.3, pp.179-86, 1969.

S. Mathias, U. S. Nayak, and B. Isaacs, Balance in elderly patients: the « get-up and go » test, Arch Phys Med Rehabil. juin, vol.67, issue.6, pp.387-396, 1986.

M. E. Tinetti, M. Speechley, and S. F. Ginter, Risk factors for falls among elderly persons living in the community, N Engl J Med. 29 déc, vol.319, issue.26, pp.1701-1708, 1988.

A. Clegg, L. Rogers, and J. Young, Diagnostic test accuracy of simple instruments for identifying frailty in community-dwelling older people: a systematic review, Age Ageing. janv, vol.44, issue.1, pp.148-52, 2015.

M. F. Folstein, S. E. Folstein, and P. R. Mchugh, « Mini-mental state ». A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, vol.12, issue.3, pp.189-98, 1975.

K. I. Shulman, D. P. Gold, C. A. Cohen, and C. A. Zucchero, Clock-drawing and dementia in the community: A longitudinal study, Int J Geriatr Psychiatry, vol.8, issue.6, pp.487-96, 1993.

P. Cowppli-bony, C. Fabrigoule, L. Letenneur, K. Ritchie, A. Alpérovitch et al.,

, Alzheimer dans la population générale, Le test des 5 mots : validité dans la détection de la maladie d, 2008.

D. Sur,

J. A. Yesavage, T. L. Brink, T. L. Rose, O. Lum, V. Huang et al., Development and validation of a geriatric depression screening scale: a preliminary report, J Psychiatr Res, vol.17, issue.1, pp.37-49, 19831982.

L. G. Marc, P. J. Raue, and M. L. Bruce, Screening Performance of the Geriatric Depression Scale (GDS-15) in a Diverse Elderly Home Care Population, Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry, vol.16, issue.11, pp.914-935, 2008.

J. P. Clément, R. F. Nassif, J. M. Léger, and F. Marchan,

, L'Encephale. avr, vol.23, issue.2, pp.91-100, 1997.

K. E. Schmader, J. T. Hanlon, C. F. Pieper, R. Sloane, C. M. Ruby et al., Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly, Am J Med. 15 mars, vol.116, issue.6, pp.394-401, 2004.

C. M. Willlams, Using medications appropriately in older adults, Am Fam Physician, vol.66, issue.10, pp.1917-1941, 2002.

M. E. Charlson, P. Pompei, K. L. Ales, and C. R. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation, J Chronic Dis. janv, vol.40, issue.5, pp.373-83, 1987.

P. A. Parmelee, P. D. Thuras, I. R. Katz, and M. P. Lawton, Validation of the Cumulative Illness Rating Scale in a geriatric residential population, J Am Geriatr Soc. févr, vol.43, issue.2, pp.130-137, 1995.

K. Rockwood, R. A. Fox, P. Stolee, D. Robertson, and B. L. Beattie, Frailty in elderly people: an evolving concept, CMAJ Can Med Assoc J. 15 févr, vol.150, issue.4, pp.489-95, 1994.

L. P. Fried, C. M. Tangen, J. Walston, A. B. Newman, C. Hirsch et al., Frailty in older adults: evidence for a phenotype, J Gerontol A Biol Sci Med Sci. mars, vol.56, issue.3, pp.146-156, 2001.

A. Clegg, J. Young, S. Iliffe, M. O. Rikkert, and K. Rockwood, Frailty in elderly people, Lancet Lond Engl. 2 mars, vol.381, issue.9868, pp.752-62, 2013.

P. Soubeyran, C. Bellera, J. Goyard, D. Heitz, H. Curé et al., Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study

B. O. Williams, PLoS ONE. 11 déc, vol.9, issue.12, p.115060, 2014.

L. Decoster, K. Van-puyvelde, S. Mohile, U. Wedding, U. Basso et al., Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations ?, Ann Oncol Off J Eur Soc Med Oncol. févr, vol.26, issue.2, pp.288-300, 2015.

, Frailty as a Predictor | SIOG

M. Extermann, I. Boler, R. R. Reich, G. H. Lyman, R. H. Brown et al., Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score, Cancer. 1 juill, vol.118, issue.13, pp.3377-86, 2012.

P. Soubeyran, M. Fonck, C. Blanc-bisson, J. Blanc, J. Ceccaldi et al., Predictors of early death risk in older patients treated with first-line chemotherapy for cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, issue.15, pp.1829-1863, 2012.

A. Hurria, K. Togawa, S. G. Mohile, C. Owusu, H. D. Klepin et al., Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study, J Clin Oncol. sept, vol.29, issue.25, pp.3457-65, 2011.

A. Hurria, S. Mohile, A. Gajra, H. Klepin, H. Muss et al., Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer, J Clin Oncol. 10 juill, vol.34, issue.20, pp.2366-71, 2016.

S. G. Mohile, W. Dale, M. R. Somerfield, M. A. Schonberg, C. M. Boyd et al., Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology, J Clin Oncol Off J Am Soc Clin Oncol. 1 août, vol.36, issue.22, pp.2326-2373, 2018.

P. Soubeyran, C. Terret, C. Bellera, F. Bonnetain, O. S. Jean et al., Role of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial, BMC Cancer, vol.01, issue.1, p.932, 2016.

E. Quoix, G. Zalcman, J. Oster, V. Westeel, E. Pichon et al., Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, Lancet Lond Engl. 17 sept, vol.378, issue.9796, pp.1079-88, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00718837

T. F. Nishijima, S. S. Shachar, K. A. Nyrop, and H. B. Muss, Safety and Tolerability of PD-1/PD-L1

, Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. The Oncologist, vol.22, pp.470-479, 2017.

L. F. Hutchins, J. M. Unger, J. J. Crowley, C. A. Coltman, and K. S. Albain, Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials, N Engl J Med. 30 déc, vol.341, issue.27, pp.2061-2068, 1999.

L. Talarico, G. Chen, and R. Pazdur, Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration, J Clin Oncol, vol.22, issue.22, pp.4626-4657, 2004.

H. Singh, B. Kanapuru, C. Smith, L. A. Fashoyin-aje, A. Myers et al., FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration, J Clin Oncol, vol.35, pp.10009-10009, 2017.

C. A. Townsley, R. Selby, and L. L. Siu, Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials, J Clin Oncol Off J Am Soc Clin Oncol. 1 mai, vol.23, issue.13, pp.3112-3136, 2005.

C. A. Townsley, K. K. Chan, G. R. Pond, C. Marquez, L. L. Siu et al., Understanding the attitudes of the elderly towards enrolment into cancer clinical trials, BMC Cancer. 8 févr, vol.6, p.34, 2006.

H. Herin, S. Aspeslagh, E. Castanon, V. Dyevre, A. Marabelle et al., Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours, Eur J Cancer. mai, vol.95, pp.68-74, 2018.

P. A. Bretscher, A two-step, two-signal model for the primary activation of precursor helper T cells, Proc Natl Acad Sci. 5 janv, vol.96, issue.1, pp.185-90, 1999.

E. A. Tivol, F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone et al., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, Immunity. nov, vol.3, issue.5, pp.541-548, 1995.

P. Waterhouse, J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian et al., Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science, vol.270, pp.985-993, 1995.

H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity. août, vol.11, issue.2, pp.141-51, 1999.

G. J. Freeman, A. J. Long, Y. Iwai, K. Bourque, T. Chernova et al., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, vol.192, issue.7, pp.1027-1061, 2000.

V. A. Boussiotis, Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

D. L. Longo, J. Engl, and . Med, , vol.375, pp.1767-78, 2016.

D. Hanahan and R. A. Weinberg, The hallmarks of cancer, Cell. 7 janv, vol.100, issue.1, pp.57-70, 2000.

L. Zitvogel, A. Tesniere, and G. Kroemer, Cancer despite immunosurveillance: immunoselection and immunosubversion, Nat Rev Immunol. oct, vol.6, issue.10, pp.715-742, 2006.

G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, vol.3, issue.11, pp.991-999, 2002.

J. P. Allison, A. A. Hurwitz, and D. R. Leach, Manipulation of costimulatory signals to enhance antitumor T-cell responses, Curr Opin Immunol. oct, vol.7, issue.5, pp.682-688, 1995.

D. R. Leach, M. F. Krummel, and J. P. Allison, Enhancement of Antitumor Immunity by CTLA-4

, Blockade. Science. 22 mars, vol.271, issue.5256, pp.1734-1740, 1996.

F. S. Hodi, S. J. O'day, D. F. Mcdermott, R. W. Weber, J. A. Sosman et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, N Engl J Med. 19 août, vol.363, issue.8, pp.711-734, 2010.

S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith et al., Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer, N Engl J Med. 28 juin, vol.366, issue.26, pp.2443-54, 2012.

M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, issue.19, pp.1823-1856, 2016.

P. J. Linton and K. Dorshkind, Age-related changes in lymphocyte development and function

, Nat Immunol. févr, vol.5, issue.2, pp.133-142, 2004.

A. E. Grulich, M. T. Van-leeuwen, M. O. Falster, and C. M. Vajdic, Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis, Lancet Lond Engl. 7 juill, vol.370, issue.9581, pp.59-67, 2007.

G. Pawelec, J. Lustgarten, C. Ruby, and C. Gravekamp, Impact of aging on cancer immunity and immunotherapy, Cancer Immunol Immunother. déc, vol.58, issue.12, pp.1907-1915, 2009.

H. Geiger and G. Van-zant, The aging of lympho-hematopoietic stem cells, Nat Immunol. avr, vol.3, issue.4, pp.329-362, 2002.

R. A. French, S. R. Broussard, W. A. Meier, C. Minshall, S. Arkins et al., Ageassociated loss of bone marrow hematopoietic cells is reversed by GH and accompanies thymic reconstitution, Endocrinology. févr, vol.143, issue.2, pp.690-699, 2002.

J. P. Miller and D. Allman, The Decline in B Lymphopoiesis in Aged Mice Reflects Loss of Very Early B-Lineage Precursors, J Immunol. 1 sept, vol.171, issue.5, pp.2326-2356, 2003.

P. Szabo, S. Shen, W. Telford, and M. E. Weksler, Impaired rearrangement of IgH V to DJ segments in bone marrow Pro-B cells from old mice, Cell Immunol. mars, vol.222, issue.1, pp.78-87, 2003.

K. M. Johnson, K. Owen, and P. L. Witte, Aging and developmental transitions in the B cell lineage, Int Immunol, vol.14, issue.11, pp.1313-1336, 2002.

T. Makinodan and M. M. Kay, Age influence on the immune system, Adv Immunol, vol.29, pp.287-330, 1980.

, Immunological studies of aging. II. Loss of IgG and high avidity plaque-forming cells and increased suppressor cell activity in aging mice

D. Sur,

B. Zheng, S. Han, Y. Takahashi, and G. Kelsoe, Immunosenescence and germinal center reaction, Immunol Rev. déc, vol.160, pp.63-77, 1997.

B. D. Jamieson, D. C. Douek, S. Killian, L. E. Hultin, D. D. Scripture-adams et al., Generation of functional thymocytes in the human adult, Immunity. mai, vol.10, issue.5, pp.569-75, 1999.

R. B. Effros, Z. Cai, and P. Linton, CD8 T cells and aging, Crit Rev Immunol, vol.23, issue.1-2, pp.45-64, 2003.

P. J. Linton, L. Haynes, N. R. Klinman, and S. L. Swain, Antigen-independent changes in naive CD4 T cells with aging, J Exp Med, vol.184, issue.5, pp.1891-900, 1996.

L. Haynes, S. M. Eaton, E. M. Burns, T. D. Randall, and S. L. Swain, CD4 T cell memory derived from young naive cells functions well into old age, but memory generated from aged naive cells functions poorly, Proc Natl Acad Sci, vol.100, issue.25, pp.15053-15061, 2003.

J. Po, E. M. Gardner, F. Anaraki, P. D. Katsikis, and D. M. Murasko, Age-associated decrease in virus-specific CD8+ T lymphocytes during primary influenza infection, Mech Ageing Dev, vol.123, issue.8, pp.1167-81, 2002.

L. Haynes and A. C. Maue, Effects of aging on T cell function, Curr Opin Immunol. août, vol.21, issue.4, pp.414-421, 2009.

Q. Leng, Z. Bentwich, and G. Borkow, CTLA-4 upregulation during aging, Mech Ageing Dev. juill, vol.123, issue.10, pp.1419-1440, 2002.

D. H. Canaday, K. E. Parker, H. Aung, H. Chen, D. Nunez-medina et al., Age-dependent changes in the expression of regulatory cell surface ligands in activated human T-cells, BMC Immunol, vol.14, issue.1, p.45, 2013.

A. R. Manser and M. Uhrberg, Age-related changes in natural killer cell repertoires: impact on NK cell function and immune surveillance, Cancer Immunol Immunother CII. avr, vol.65, issue.4, pp.417-443, 2016.

J. Lloberas and A. Celada, Effect of aging on macrophage function, Exp Gerontol. déc, vol.37, issue.12, pp.1325-1356, 2002.

C. Sileni, V. Pigozzo, J. Ascierto, P. A. Grimaldi, A. M. Maio et al., Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme, J Exp Clin Cancer Res CR. 4 avr, vol.33, issue.1, p.30, 2014.

C. Robert, G. V. Long, B. Brady, C. Dutriaux, M. Maio et al., Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med. 22 janv, vol.372, issue.4, pp.320-350, 2015.

J. S. Weber, S. P. Angelo, D. Minor, F. S. Hodi, R. Gutzmer et al., Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol. avr, vol.16, issue.4, pp.375-84, 2015.

J. Schachter, A. Ribas, G. V. Long, A. Arance, J. Grob et al., Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). The Lancet, vol.390, pp.1853-62, 2017.

, Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | NEJM

D. Sur, Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM

D. Sur,

C. F. Friedman, T. Z. Horvat, J. Minehart, K. Panageas, M. K. Callahan et al., Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+), J Clin Oncol. 20 mai, vol.34, pp.10009-10009, 2016.

T. Ibrahim, C. Mateus, M. Baz, and C. Robert, Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study, Cancer Immunol Immunother. oct, vol.67, issue.10, pp.1571-1579, 2018.

C. F. Friedman and J. D. Wolchok, Checkpoint Inhibition and Melanoma: Considerations in Treating the Older Adult, J Geriatr Oncol. juill, vol.8, issue.4, pp.237-278, 2017.

L. Gandhi, D. Rodríguez-abreu, S. Gadgeel, E. E. Felip, E. et al., IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC, Journal of Clinical Oncology, vol.378, issue.22, pp.2078-92, 2018.

D. Sur,

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015.

O. Molinier, B. Besse, F. Barlesi, C. Audigier-valette, S. Friard et al., IFCT 1502-CLINIVO : efficacité et tolérance du nivolumab et du traitement post-nivolumab dans le cancer bronchique non à petites cellules au stade avancé. Une étude en vie réelle dans le cadre de l'ATU nivolumab, Rev Mal Respir. janv, vol.35, p.8, 2015.

R. S. Herbst, P. Baas, D. Kim, E. Felip, J. L. Pérez-gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet, vol.9, pp.1540-50, 2016.

M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater, J Clin Oncol. 8 janv, vol.37, issue.7, pp.537-583, 2019.

D. P. Carbone, M. Reck, L. Paz-ares, B. Creelan, L. Horn et al., First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, N Engl J Med. 22 juin, vol.376, issue.25, pp.2415-2441, 2017.

A. Ravaud, S. Negrier, F. Lakdja, A. Mercatello, L. Cany et al.,

, Bull Cancer (Paris), vol.78, pp.989-1005, 1991.

. Nous-m-de-l'urologie,

. L'expérience-du-groupe-français-d'immunothérapie, , 2018.

R. J. Motzer, B. Escudier, D. F. Mcdermott, S. George, H. J. Hammers et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.373, pp.1803-1816, 2015.

R. J. Motzer, N. M. Tannir, D. F. Mcdermott, A. Frontera, O. Melichar et al., Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N Engl J Med. 5 avr, vol.378, issue.14, pp.1277-90, 2018.

D. Cella, V. Grünwald, B. Escudier, H. J. Hammers, S. George et al., Patientreported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, Lancet Oncol. 1 févr, vol.20, issue.2, pp.297-310, 2019.

H. Von-der-maase, S. W. Hansen, J. T. Roberts, L. Dogliotti, T. Oliver et al., Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study, J Clin Oncol Off J Am Soc Clin Oncol. sept, vol.18, issue.17, pp.3068-77, 2000.

M. De-santis, J. Bellmunt, G. Mead, J. M. Kerst, M. Leahy et al., Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986, J Clin Oncol Off J Am Soc Clin Oncol. 10 janv, vol.30, issue.2, pp.191-200, 2012.

Y. Fradet, J. Bellmunt, D. J. Vaughn, J. L. Lee, L. Fong et al., Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up, Ann Oncol

D. Sur,

T. Powles, I. Durán, . Heijden-ms-van-der, Y. Loriot, N. J. Vogelzang et al., Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. The Lancet, vol.24, pp.748-57, 2018.

P. Sharma, M. Retz, A. Siefker-radtke, A. Baron, A. Necchi et al., Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, Lancet Oncol, vol.18, issue.3, pp.312-334, 2017.

M. R. Patel, J. Ellerton, J. R. Infante, M. Agrawal, M. Gordon et al., Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial, Lancet Oncol, vol.19, issue.1, pp.51-64, 2018.

C. Massard, M. S. Gordon, S. Sharma, S. Rafii, Z. A. Wainberg et al., Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.10, issue.26, pp.3119-3144, 2016.

, First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study -The Lancet Oncology

D. Sur,

A. V. Balar, M. D. Galsky, J. E. Rosenberg, T. Powles, D. P. Petrylak et al., Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, Lancet Lond Engl, vol.07, pp.67-76, 2017.

, Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck | NEJM

D. Sur,

T. Y. Seiwert, B. Burtness, R. Mehra, J. Weiss, R. Berger et al., Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial, Lancet Oncol. juill, vol.17, issue.7, pp.956-65, 2016.

E. Cohen, D. Soulières, C. L. Tourneau, J. Dinis, L. Licitra et al., Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. The Lancet, janv, vol.12, pp.156-67, 2019.

M. A. Postow, R. Sidlow, and M. D. Hellmann, Immune-Related Adverse Events Associated with Immune Checkpoint Blockade, N Engl J Med. 11 janv, vol.378, issue.2, pp.158-68, 2018.

J. S. Weber, K. C. Kähler, and A. Hauschild, Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab, J Clin Oncol. 21 mai, vol.30, issue.21, pp.2691-2698, 2012.

S. Champiat, O. Lambotte, E. Barreau, R. Belkhir, A. Berdelou et al., Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

, Ann Oncol. avr, vol.27, issue.4, pp.559-74, 2016.

S. Champiat, O. Lambotte, E. Barreau, R. Belkhir, A. Berdelou et al., Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

, Ann Oncol. 1 avr, vol.27, issue.4, pp.559-74, 2016.

M. D. Miller, C. F. Paradis, P. R. Houck, S. Mazumdar, J. A. Stack et al., Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale, Psychiatry Res. mars, vol.41, issue.3, pp.237-285, 1992.

H. Quan, B. Li, C. M. Couris, K. Fushimi, P. Graham et al., Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries, Am J Epidemiol. 15 mars, vol.173, issue.6, pp.676-82, 2011.

E. Muchnik, K. P. Loh, M. Strawderman, A. Magnuson, S. G. Mohile et al., Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer: IMMUNE CHECKPOINT INHIBITORS AND OLDER ADULTS, J Am Geriatr Soc, 2019.

D. Sur,

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux. Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences. Je donnerai mes soins à l'indigent et à quiconque me les demandera. Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire. admis(e) dans l'intimité des personnes, je tairai les secrets qui me seront confiés. reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma, J'informerai les patients des décisions envisagées, de leurs raisons et de leurs conséquences

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément. Je préserverai l'indépendance nécessaire à l'accomplissement de ma

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré(e) et méprisé(e) si j'y manque. Introduction : Les essais prospectifs disponibles d'immunothérapies par inhibiteurs de points de contrôle de l'immunité (CPI) n'

;. Méthodes, . Bergonié, and . Chu-de-bordeaux, Cette étude rétrospective s'intéressait aux patients de plus de 70 ans traités par CPI (anti PD-1, PD-L1 et/ou CTLA-4) entre, 2014.

, L'objectif principal de notre étude était d'évaluer la prévalence des toxicités sévères, définies comme le décès toxique, l'arrêt définitif du traitement pour toxicité, la nécessité d'une hospitalisation pour mise en place d'une corticothérapie du fait d'une toxicité, et/ou l'instauration d'une corticothérapie à plus de 0,7mg/kg pour plus de 2 semaines. L'objectif secondaire consistait à rechercher des associations entre ces toxicités sévères

, Le taux de réponse objective était de 27,8% sans paramètre statistiquement associé. Il existait en association entre réponse ou stabilisation et le bon performans status, Résultats : 194 patients ont été inclus, 139 étaient des hommes (71,6%) dont l'âge médian était de 75 ans. 24 patients soit 12,4% de l'effectif (IC95 7-17%) ont présenté une toxicité grave imputable au traitement

, Il faut encourager l'inclusion de patients âgés dans les essais prospectifs et la réalisation d'essais onco-gériatriques. Introduction: Checkpoint Inhibitors (CPI) have greatly modified the management of many advanced cancers, Conclusion : Les prescriptions de CPI sont envisageables chez les sujets âgés en termes de toxicité et d'efficacité au vu de ces données

, The primary objective was to evaluate the prevalence of severe toxicities, defined as toxic death, definitive discontinuation of the treatment for toxicity, hospitalization requirement for the implementation of corticosteroid therapy because of a toxicity, and / or initiation of corticosteroid therapy above 0.7 mg / kg for more than 2 weeks. The secondary objective was to retrieve associations between these severe toxicities, efficacy define by disease response and parameters of interest, Methods: This retrospective study focuses on patients over 70 years old treated with CPI (anti-PD-1, anti PD-L1 anti CTLA-4) between, pp.95-102, 2014.